Zobrazeno 1 - 10
of 373
pro vyhledávání: '"Kyung-Hae Jung"'
Autor:
Tae-Kyung Robyn Yoo, Ji-Young Lee, Hwan Park, Whi-Kyung Cho, Seyeon Jeon, Ha Ra Jun, Sae Byul Lee, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Sei-Hyun Ahn, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Hee Jin Lee, Gyungyub Gong, Jisun Kim, Sung-Min Chun
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with breast cancer recurrence or de novo metastatic cancer were examined in a retrospective analysis of a prospective observational cohort. Twenty-three recurrent/metas
Externí odkaz:
https://doaj.org/article/e1adfca4ed3f4f3b94a726a99969be43
Autor:
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with t
Externí odkaz:
https://doaj.org/article/3cba658e7441401e9b9e50ad16a29171
Autor:
Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. To develop a differentiated HER2 ADC, we chose an antibody that does not compete with trastuzumab or pertuzuma
Externí odkaz:
https://doaj.org/article/654b41b090ea4a87be21fb42ec554dae
Autor:
Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won Lee, Keun Seok Lee, Joohyuk Sohn, Kyung Hae Jung, In Hae Park
Publikováno v:
Breast, Vol 65, Iss , Pp 172-178 (2022)
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
Externí odkaz:
https://doaj.org/article/330f949c2ee044c8b4039cf8ac994503
Autor:
Joseph Gligorov, Xavier Pivot, Beyhan Ataseven, Michelino De Laurentiis, Kyung Hae Jung, Alexey Manikhas, Hamdy Abdel Azim, Kushagra Gupta, Ari Alexandrou, Luis Herraez-Baranda, Nadia Tosti, Eleonora Restuccia
Publikováno v:
Breast, Vol 64, Iss , Pp 151-158 (2022)
Aim: To report the final results of the 5-year follow-up of the non-randomized SafeHER Phase III study (NCT01566721) describing the safety, tolerability, and efficacy of subcutaneous (SC) trastuzumab alone and in combination with concurrent or sequen
Externí odkaz:
https://doaj.org/article/17375d004c944ad6ba82bb82c1a364c7
Autor:
Sun Young Chae, Seol Hoon Park, Hyo Sang Lee, Jin-Hee Ahn, Sung-Bae Kim, Kyung Hae Jung, Jeong Eun Kim, Sei Hyun Ahn, Byung Ho Son, Jong Won Lee, Beom Seok Ko, Hee Jeong Kim, Gyungyub Gong, Jungsu S. Oh, Seo Young Park, Dae Hyuk Moon
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract We examined whether 18F-fluorodeoxyglucose metabolism is associated with distant relapse-free survival (DRFS) and overall survival (OS) in women with estrogen receptor (ER)-positive, HER2-negative breast cancer. This was a cohort study exami
Externí odkaz:
https://doaj.org/article/3584102ec98d4666b689ca57e1ede57d
Autor:
Soohyeon Lee, Kyunghee Park, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Woong-Yang Park, Seock-Ah Im, Yeon Hee Park
Publikováno v:
Breast, Vol 62, Iss , Pp 52-60 (2022)
Background: Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase ll trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone recept
Externí odkaz:
https://doaj.org/article/30a55aa347d34ca5a2ac5cb61a35e935
Autor:
Jwa Hoon Kim, Seyoung Seo, Jee Hyun Kim, Su‐Jin Koh, Yongchel Ahn, Kyung Hae Jung, Jin‐Hee Ahn, Sung‐Bae Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang‐We Kim, Dae Ho Lee, Jae Cheol Lee, Chang‐Min Choi, Shinkyo Yoon, Jae Ho Jeong, Hwa Jung Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Young Joo Min, Jin Ho Baek, Sook Ryun Park
Publikováno v:
Cancer Medicine, Vol 11, Iss 3, Pp 705-714 (2022)
Abstract Background This study was conducted to compare the reported adverse event (AE) profiles and unexpected use of medical services during chemotherapy between before and after the healthcare reimbursement of AE evaluation in patients with cancer
Externí odkaz:
https://doaj.org/article/3bdcf0564de7494bb68a4b26fe0b4105
Autor:
Ho Hyun Ryu, Sei Hyun Ahn, Seon Ok Kim, Jeong Eun Kim, Ji sun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Hee Jung Shin, Hak Hee Kim, Gyung yub Gong, Hee Jeong Kim
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Survival of breast cancer patients has improved, and treatment-related changes regarding metabolic profile deterioration after neoadjuvant systemic treatment (NST) become important issues in cancer survivors. We sought to compare metabolic p
Externí odkaz:
https://doaj.org/article/2e12df5d86484ac796ec0eb06330249b
Autor:
Sun Min Lim, Eunyoung Kim, Kyung Hae Jung, Sora Kim, Ja Seung Koo, Seung Il Kim, Seho Park, Hyung Seok Park, Byoung Woo Park, Young Up Cho, Ji Ye Kim, Soonmyung Paik, Nak-Jung Kwon, Gun Min Kim, Ji Hyoung Kim, Min Hwan Kim, Min Kyung Jeon, Sangwoo Kim, Joohyuk Sohn
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-9 (2021)
Lim, Kim and Jung et al. report a whole-exome sequence analysis of 30 Korean patients showing extreme treatment responses for metastatic breast cancer. They find that compared to non-responders, extreme responders have fewer nonsynonymous mutations a
Externí odkaz:
https://doaj.org/article/88ab653ac0f34cc590341be94ab057d0